Citadel Advisors’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.9M | Sell |
110,600
-77,800
| -41% | -$11.9M | ﹤0.01% | 2537 |
|
|
2025
Q4 | $26M | Buy |
188,400
+9,200
| +5% | +$1.2M | ﹤0.01% | 2061 |
|
|
2025
Q3 | $23M | Buy |
179,200
+51,900
| +41% | +$6.33M | ﹤0.01% | 2157 |
|
|
2025
Q2 | $15.4M | Buy |
127,300
+41,700
| +49% | +$4.7M | ﹤0.01% | 2468 |
|
|
2025
Q1 | $9.54M | Sell |
85,600
-175,200
| -67% | -$18.7M | ﹤0.01% | 2916 |
|
|
2024
Q4 | $25.4M | Buy |
260,800
+152,900
| +142% | +$16.3M | ﹤0.01% | 1908 |
|
|
2024
Q3 | $12.4M | Buy |
107,900
+25,400
| +31% | +$2.88M | ﹤0.01% | 2603 |
|
|
2024
Q2 | $8.78M | Sell |
82,500
-31,400
| -28% | -$3.15M | ﹤0.01% | 2943 |
|
|
2024
Q1 | $11M | Sell |
113,900
-163,100
| -59% | -$16.7M | ﹤0.01% | 2819 |
|
|
2023
Q4 | $28M | Buy |
277,000
+106,600
| +63% | +$10.3M | 0.01% | 1698 |
|
|
2023
Q3 | $17.4M | Sell |
170,400
-282,100
| -62% | -$28.6M | ﹤0.01% | 2013 |
|
|
2023
Q2 | $45.7M | Buy |
452,500
+11,800
| +3% | +$1.18M | 0.01% | 1121 |
|
|
2023
Q1 | $40.5M | Sell |
440,700
-440,500
| -50% | -$38.5M | 0.01% | 1257 |
|
|
2022
Q4 | $79.9M | Buy |
881,200
+144,600
| +20% | +$12.2M | 0.02% | 773 |
|
|
2022
Q3 | $56M | Sell |
736,600
-33,900
| -4% | -$2.81M | 0.01% | 979 |
|
|
2022
Q2 | $65.1M | Buy |
770,500
+327,000
| +74% | +$28.7M | 0.02% | 839 |
|
|
2022
Q1 | $38.9M | Sell |
443,500
-244,100
| -36% | -$21.1M | 0.01% | 1315 |
|
|
2021
Q4 | $60.1M | Buy |
687,600
+286,000
| +71% | +$23.7M | 0.01% | 1031 |
|
|
2021
Q3 | $32.8M | Buy |
401,600
+176,700
| +79% | +$15.9M | 0.01% | 1492 |
|
|
2021
Q2 | $20.5M | Buy |
224,900
+4,900
| +2% | +$436K | ﹤0.01% | 2047 |
|
|
2021
Q1 | $18.8M | Buy |
220,000
+65,900
| +43% | +$5.91M | ﹤0.01% | 2047 |
|
|
2020
Q4 | $14.6M | Buy |
154,100
+37,000
| +32% | +$3.23M | ﹤0.01% | 2165 |
|
|
2020
Q3 | $10.2M | Sell |
117,100
-24,200
| -17% | -$2.1M | ﹤0.01% | 2273 |
|
|
2020
Q2 | $12.3M | Sell |
141,300
-45,300
| -24% | -$3.91M | ﹤0.01% | 1990 |
|
|
2020
Q1 | $15.4M | Buy |
186,600
+89,100
| +91% | +$7.95M | 0.01% | 1454 |
|
|
2019
Q4 | $9.23M | Sell |
97,500
-65,200
| -40% | -$5.85M | ﹤0.01% | 2293 |
|
|
2019
Q3 | $14.1M | Buy |
162,700
+47,600
| +41% | +$4.27M | 0.01% | 1834 |
|
|
2019
Q2 | $10.5M | Buy |
115,100
+10,866
| +10% | +$920K | ﹤0.01% | 2118 |
|
|
2019
Q1 | $8.98M | Sell |
104,234
-29,128
| -22% | -$2.34M | ﹤0.01% | 2214 |
|
|
2018
Q4 | $10.3M | Buy |
133,362
+32,476
| +32% | +$2.53M | 0.01% | 1861 |
|
|
2018
Q3 | $7.79M | Buy |
100,886
+73,432
| +267% | +$5.43M | ﹤0.01% | 2438 |
|
|
2018
Q2 | $1.86M | Sell |
27,454
-16,293
| -37% | -$1.12M | ﹤0.01% | 4223 |
|
|
2018
Q1 | $3.17M | Sell |
43,747
-140,728
| -76% | -$10.7M | ﹤0.01% | 3067 |
|
|
2017
Q4 | $13.9M | Buy |
184,475
+134,813
| +271% | +$10.2M | 0.01% | 1416 |
|
|
2017
Q3 | $3.82M | Buy |
49,662
+28,123
| +131% | +$2.12M | ﹤0.01% | 2606 |
|
|
2017
Q2 | $1.61M | Sell |
21,539
-9,486
| -31% | -$672K | ﹤0.01% | 3446 |
|
|
2017
Q1 | $2.06M | Sell |
31,025
-56,581
| -65% | -$3.77M | ﹤0.01% | 3034 |
|
|
2016
Q4 | $5.72M | Buy |
87,606
+59,260
| +209% | +$3.84M | 0.01% | 1854 |
|
|
2016
Q3 | $2.01M | Sell |
28,346
-23,213
| -45% | -$1.69M | ﹤0.01% | 2966 |
|
|
2016
Q2 | $3.81M | Buy |
+51,559
| New | +$3.56M | ﹤0.01% | 2070 |
|
Other funds holding NVS
Citadel Advisors's NVS Position: Q2 2025 in Review
Citadel Advisors sold out of Novartis (NVS) in Q2 2025, closing a stake of 1,067,586 shares — an estimated $120M sold.
Citadel Advisors first reported a position in NVS in Q3 2013 and held it in 44 quarters. The position peaked at $119M in Q1 2025. 1,383 funds tracked by Wall St. Rank hold NVS as of Q2 2025.
- Citadel Advisors reported no remaining Novartis position as of Q2 2025 after selling out during the quarter.
- Citadel Advisors sold 1,067,586 Novartis shares in Q2 2025, an estimated $120M.
- Citadel Advisors first reported a position in Novartis in Q3 2013 and held it in 44 quarters.
- Citadel Advisors's Novartis position peaked at $119M in Q1 2025.
- 1,383 funds tracked by Wall St. Rank held Novartis as of Q2 2025.
Based on Citadel Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.